IL6 and familial pancreatic carcinoma: Combination therapy with IL6 and PD-L1 antibody administered based on these results suppressed tumor progression and prolonged overall survival in a GEMM of pancreatic cancer (Pdx1-Cre, lox-stop-lox-KrasG12D/+, lox-stop-lox-Trp53R270H/+, and Brca2lox/lox) [70].